Teva Pharma Net Worth
Teva Pharma Net Worth Breakdown | TEVA |
Teva Pharma Net Worth Analysis
Teva Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Teva Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Teva Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Teva Pharma's net worth analysis. One common approach is to calculate Teva Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Teva Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Teva Pharma's net worth. This approach calculates the present value of Teva Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Teva Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Teva Pharma's net worth. This involves comparing Teva Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Teva Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Teva Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Teva Pharma's net worth research are outlined below:
| Teva Pharma generated a negative expected return over the last 90 days | |
| Teva Pharma Industries currently holds 18.08 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Teva Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 16.54 B. Net Loss for the year was (1.96 B) with profit before overhead, payroll, taxes, and interest of 8.06 B. | |
| About 60.0% of Teva Pharma shares are owned by institutional investors | |
| Latest headline from benzinga.com: Teva Pharmaceutical Induss Options A Look at What the Big Money is Thinking |
Teva Pharma Quarterly Good Will |
|
Teva Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Teva Pharma Industries. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Teva Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Teva Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Teva Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Teva Pharma Industries backward and forwards among themselves. Teva Pharma's institutional investor refers to the entity that pools money to purchase Teva Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pointstate Capital Lp | 2024-12-31 | 13.5 M | Geode Capital Management, Llc | 2024-12-31 | 9.3 M | Australiansuper Pty Ltd | 2024-12-31 | 9.2 M | Duquesne Family Office Llc | 2024-12-31 | 9 M | Slate Path Capital Lp | 2024-12-31 | 8.5 M | Glenview Capital Management Llc | 2024-12-31 | 8.5 M | Arrowstreet Capital Limited Partnership | 2024-12-31 | 7 M | Renaissance Technologies Corp | 2024-12-31 | 7 M | Hhg Plc | 2024-12-31 | 6.7 M | Fmr Inc | 2024-12-31 | 82 M | Blackrock Inc | 2024-12-31 | 50.6 M |
Follow Teva Pharma's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 18.65 B.Market Cap |
|
Project Teva Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.08) | (0.08) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.31) | (0.29) |
When accessing Teva Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Teva Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Teva Pharma's profitability and make more informed investment decisions.
Please note, the presentation of Teva Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Teva Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Teva Pharma's management manipulating its earnings.
Evaluate Teva Pharma's management efficiency
Teva Pharma Industries has return on total asset (ROA) of 0.0509 % which means that it generated a profit of $0.0509 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.283) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.08. The current year's Return On Capital Employed is expected to grow to -0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3.3 B, whereas Total Assets are forecasted to decline to about 26.8 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.05 | 8.38 | |
| Tangible Book Value Per Share | (12.22) | (11.61) | |
| Enterprise Value Over EBITDA | 51.56 | 67.62 | |
| Price Book Value Ratio | 4.71 | 4.47 | |
| Enterprise Value Multiple | 51.56 | 67.62 | |
| Price Fair Value | 4.71 | 4.47 | |
| Enterprise Value | 32.5 B | 34.2 B |
The leadership approach at Teva Pharma's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 2.0156 | Revenue | Quarterly Revenue Growth (0.05) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Teva Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Teva Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Teva Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Teva Pharma Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
ASR | 7th of February 2025 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
10K | 5th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Teva Pharma Earnings per Share Projection vs Actual
Teva Pharma Corporate Directors
| Nechemia Peres | Independent Director | Profile | |
| JeanMichel Halfon | Statutory - independent director | Profile | |
| Perry Nisen | Independent Director | Profile | |
| Gerald Lieberman | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.45) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.